Sarah Cannon Molecular Diagnostics

As we are constantly developing and validating new tests to support and expand the existing repertoire, make sure you watch this space! We are also supported by a team of expert scientists and clinicians who help HCA clinicians interpret and act on our test results. Although we offer a full range of services in order to best fit the varied needs of customers, our core tests utilise NGS technology. We offer two principal NGS based tests which broadly correspond to two main types of therapeutic approach to cancer treatment. Why don’t we offer all of the above as one single big test? It’s a good question, and we happily admit that we are quite unusual in not doing so. The second major advantage of offering smaller panels, which are focused primarily upon clinical actionability, is that we typically need less DNA/RNA and can thus prioritise sensitivity and robustness over making them unnecessarily comprehensive. In addition to NGS based tests we also offer a range of other molecular diagnostic assays providing diagnostic, prognostic and treatment stratification related information.